Infectious disease
A day after the FDA authorized a COVID-19 booster dose of the Pfizer-BioNTech vaccine, a U.S. Centers for Disease Control and Prevention advisory committee voted in support.
FDA authorizes Pfizer-BioNTech COVID-19 booster shots for individuals 65 and over, those at high risk for severe disease and front-line healthcare workers.
On Wednesday, the company said that its adjuvanted protein-based COVID-19 vaccine candidate, dubbed SCB-2019 (CpG 1018/Alum), hit the primary and secondary efficacy endpoints in a Phase II/III clinical trial.
The survey of 20,699 Americans found that the unvaccinated – 35% of respondents – didn’t trust that the vaccines were safe or effective.
Monoclonal antibodies play a key role in the treatment of COVID-19, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies.
Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.
As the COVID-19 pandemic hit a grim milestone, marking more U.S. deaths than were reported in the 1918–19 Spanish flu pandemic, research and breakthroughs continue.
On the tailcoat of Tuesday’s United Nations General Assembly, President Biden is hosting a virtual COVID-19 summit Wednesday, calling for the end of the pandemic globally.
In September 20, 2021, the United States marked a grisly milestone, recording more American deaths from COVID-19 than died from the 1918-1919 Spanish flu pandemic.
The Phase II/III trial showed a favorable safety profile and “robust” neutralizing antibody responses in children five to 11 years old who received two 10 µg doses of the vaccine at 21 days apart.
PRESS RELEASES